STOCK TITAN

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call and live webcast on July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution. The webcast will be accessible through the company's website. Telephone participants can register to receive a confirmation email with details on how to join the call. A replay of the event will be available on Kiniksa's website within approximately 48 hours.
Positive
  • None.
Negative
  • None.

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
 


Kiniksa Pharmaceuticals will report its second quarter 2023 financial results on July 25, 2023.

The conference call and live webcast will start at 8:30 a.m. Eastern Time.

The webcast can be accessed through the Investors & Media section of Kiniksa Pharmaceuticals' website at www.kiniksa.com.

To participate in the conference call via telephone, you can register and receive a confirmation email with details on how to join the call.

Yes, a replay of the event will be available on Kiniksa Pharmaceuticals' website within approximately 48 hours after the event.
Kiniksa Pharmaceuticals Ltd

NASDAQ:KNSA

KNSA Rankings

KNSA Latest News

KNSA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing

About KNSA

kiniksa pharmaceuticals combines an experienced management team and significant committed capital in order to acquire, develop, and commercialize therapeutics treating devastating diseases with high unmet needs.